补体系统激活参与阿尔茨海默病的研究进展

doi:10.11958/20231554

天津医药 ›› 2024, Vol. 52 ›› Issue (6): 663-668.doi: 10.11958/20231554

补体系统激活参与阿尔茨海默病的研究进展

慕静然(), 骆延, 梁璇, 徐陶, 曾俊伟, 刘晓红()

遵义医科大学生理学教研室（邮编563000）

收稿日期:2023-10-11 修回日期:2023-11-20 出版日期:2024-06-15 发布日期:2024-06-06
通讯作者: ^△E-mail：xiaohongliuedu@163.com
作者简介:慕静然（1995），女，硕士在读，主要从事神经炎症方面研究。E-mail：1906420348@qq.com
基金资助:
国家自然科学基金资助项目(81960161);国家自然科学基金资助项目(31860291);贵州省教育厅创新群体重大研究项目(黔教合KY字[2018]025)

Research progress on the activation of complement system is involved in the pathogenesis of Alzheimer's disease

MU Jingran(), LUO Yan, LIANG Xuan, XU Tao, ZENG Junwei, LIU Xiaohong()

Department of Physiology, Zunyi Medical University, Zunyi 563000, China

Received:2023-10-11 Revised:2023-11-20 Published:2024-06-15 Online:2024-06-06
Contact: ^△E-mail: xiaohongliuedu@163.com

慕静然, 骆延, 梁璇, 徐陶, 曾俊伟, 刘晓红. 补体系统激活参与阿尔茨海默病的研究进展[J]. 天津医药, 2024, 52(6): 663-668.

MU Jingran, LUO Yan, LIANG Xuan, XU Tao, ZENG Junwei, LIU Xiaohong. Research progress on the activation of complement system is involved in the pathogenesis of Alzheimer's disease[J]. Tianjin Medical Journal, 2024, 52(6): 663-668.

摘要/Abstract

摘要：

阿尔茨海默病（AD）是一种常见的神经系统退行性疾病。补体系统激活在AD病变进程中发挥了重要作用，活化的补体可与膜受体结合，调节下游信号发挥作用。抑制补体激活为AD治疗提供了新思路。就有关补体系统激活参与AD病变的机制以及相应的药物研发进展进行综述，以期为AD的诊断、治疗及药物研发提供新观点。

关键词: 阿尔茨海默病, 补体系统蛋白质类, 淀粉样β肽类, 突触, tau蛋白质类, 胶质细胞, 神经炎症

Abstract:

Alzheimer's disease (AD) is a common neurodegenerative disease, which is mainly caused by brain lesions. The activation of complement system plays an important role in the process of AD lesions. The activated complement can bind to cell membrane receptors and regulate downstream signals. Therefore, inhibiting complement activation provides a new idea for AD treatment. This article reviews the progress in the mechanism and drug development of complement activation in AD, which may provide a new perspective for the diagnosis, treatment and drug development of AD.

Key words: Alzheimer disease, complement system proteins, amyloid beta-peptides, synapses, tau proteins, colloid cell, neuroinflammation

中图分类号:

R745.7

参考文献 41

[1]	邵蕊, 李岱, 韩召利, 等. 基于老年综合评估的个体化康复训练对阿尔茨海默病患者认知功能、风险防范的影响[J]. 天津医药, 2021, 49(8):847-851.
	SHAO R, LI D, HAN Z L, et al. Effects of individualized rehabilitation training based on comprehensive geriatric assessment on cognitive function and risk prevention of patients with Alzheimer's disease[J]. Tianjin Med J, 2021, 49(8):847-851. doi:10.11958/20210643.
[2]	YANG J, WISE L, FUKUCHI K I. TLR4 cross-talk with NLRP3 inflammasome and complement signaling pathways in Alzheimer's disease[J]. Front Immunol, 2020, 11:724. doi:10.3389/fimmu.2020.00724.
[3]	YIN C, ACKERMANN S, MA Z, et al. ApoE attenuates unresolvable inflammation by complex formation with activated C1q[J]. Nat Med, 2019, 25(3):496-506. doi:10.1038/s41591-018-0336-8.
[4]	SHAH A, KISHORE U, SHASTRI A. Complement system in Alzheimer's disease[J]. Int J Mol Sci, 2021, 22(24):13647. doi:10.3390/ijms222413647.
[5]	FATOBA O, ITOKAZU T, YAMASHITA T. Complement cascade functions during brain development and neurodegeneration[J]. FEBS J, 2022, 289(8):2085-2109. doi:10.1111/febs.15772.
[6]	CHEN W T, LU A, CRAESSAERTS K, et al. Spatial transcriptomics and in situ sequencing to study Alzheimer's disease[J]. Cell, 2020, 182(4):976-991.e19. doi:10.1016/j.cell.2020.06.038.
[7]	WU T, DEJANOVIC B, GANDHAM V D, et al. Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy[J]. Cell Rep, 2019, 28(8):2111-2123.e6. doi:10.1016/j.celrep.2019.07.060.
[8]	LIAN H, YANG L, COLE A, et al. NFκB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease[J]. Neuron, 2015, 85(1):101-115. doi:10.1016/j.neuron.2014.11.018.
[9]	LITVINCHUK A, WAN Y W, SWARTZLANDER D B, et al. Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer's disease[J]. Neuron, 2018, 100(6):1337-1353.e5. doi:10.1016/j.neuron.2018.10.031.
[10]	ZHANG D F, FAN Y, XU M, et al. Complement C7 is a novel risk gene for Alzheimer's disease in Han Chinese[J]. Natl Sci Rev, 2019, 6(2):257-274. doi:10.1093/nsr/nwy127.
[11]	YUAN H, DU L, GE P. Complement receptor 1 genetic polymorphism contributes to sporadic Alzheimer's disease susceptibility in Caucasians: a meta-analysis[J]. Biosci Rep, 2020, 40(6):BSR20200321. doi:10.1042/BSR20200321.
[12]	MAHMOUDI R, FELDMAN S, KISSERLI A, et al. Inherited and acquired decrease in complement receptor 1(CR1)density on red blood cells associated with high levels of soluble CR1 in Alzheimer's disease[J]. Int J Mol Sci, 2018, 19(8):2175. doi:10.3390/ijms19082175.
[13]	CAI H, PANG Y, WANG Q, et al. Proteomic profiling of circulating plasma exosomes reveals novel biomarkers of Alzheimer's disease[J]. Alzheimers Res Ther, 2022, 14(1):181. doi:10.1186/s13195-022-01133-1.
[14]	GOETZL E J, SCHWARTZ J B, ABNER E L, et al. High complement levels in astrocyte-derived exosomes of Alzheimer disease[J]. Ann Neurol, 2018, 83(3):544-552. doi:10.1002/ana.25172.
[15]	NOGUERAS-ORTIZ C J, MAHAIRAKI V, DELGADO-PERAZA F, et al. Astrocyte- and neuron-derived extracellular vesicles from Alzheimer's disease patients effect complement-mediated neurotoxicity[J]. Cells, 2020, 9(7):1618. doi:10.3390/cells9071618.
[16]	FLORENTINUS-MEFAILOSKI A, BOWDEN P, SCHELTENS P, et al. The plasma peptides of Alzheimer's disease[J]. Clin Proteomics, 2021, 18(1):17. doi:10.1186/s12014-021-09320-2.
[17]	BONHAM L W, DESIKAN R S, YOKOYAMA J S, et al. The relationship between complement factor C3,APOE ε4,amyloid and tau in Alzheimer's disease[J]. Acta Neuropathol Commun, 2016, 4(1):65. doi:10.1186/s40478-016-0339-y.
[18]	LU G, LIU W, HUANG X, et al. Complement factor H levels are decreased and correlated with serum C-reactive protein in late-onset Alzheimer's disease[J]. Arq Neuropsiquiatr, 2020, 78(2):76-80. doi:10.1590/0004-282X20190151.
[19]	王翠, 杨畅, 金玉, 等. 木犀草苷对阿尔茨海默病模型细胞凋亡和炎性因子表达的研究[J]. 天津医药, 2023, 51(7):701-706.
	WANG C, YANG C, JIN Y, et al. Study of cynaroside on apoptosis and expression of inflammatory factor in model cells of Alzheimer's disease[J]. Tianjin Med J, 2023, 51(7):701-706. doi:10.11958/20221922.
[20]	CHERNYAEVA L, RATTI G, TEIRILÄ L, et al. Reduced binding of ApoE4 to complement factor H promotes amyloid-β oligomerization and neuroinflammation[J]. EMBO Rep, 2023, 24(7):e56467. doi:10.15252/embr.202256467.
[21]	BISHT K, SHARMA K, TREMBLAY M È. Chronic stress as a risk factor for Alzheimer's disease:Roles of microglia-mediated synaptic remodeling,inflammation,and oxidative stress[J]. Neurobiol Stress, 2018, 9:9-21. doi:10.1016/j.ynstr.2018.05.003.
[22]	ROY E R, WANG B, WAN Y W, et al. Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease[J]. J Clin Invest, 2020, 130(4):1912-1930. doi:10.1172/JCI133737.
[23]	LIAN H, LITVINCHUK A, CHIANG A C, et al. Astrocyte-microglia cross talk through complement activation modulates amyloid pathology in mouse models of Alzheimer's disease[J]. J Neurosci, 2016, 36(2):577-589. doi:10.1523/JNEUROSCI.2117-15.2016.
[24]	GUAN P P, GE T Q, WANG P. As a potential therapeutic target,C1q induces synapse loss via inflammasome-activating apoptotic and mitochondria impairment mechanisms in Alzheimer's disease[J]. J Neuroimmune Pharmacol, 2023, 18(3):267-284. doi:10.1007/s11481-023-10076-9.
[25]	AN X Q, XI W, GU C Y, et al. Complement protein C5a enhances the β-amyloid-induced neuro-inflammatory response in microglia in Alzheimer's disease[J]. Med Sci(Paris), 2018,34 Focus issue F1:116-120. doi:10.1051/medsci/201834f120.
[26]	KRETZSCHMAR G C, BUMILLER-BINI V, GASPARETTO FILHO M A, et al. Neutrophil extracellular traps:A perspective of neuroinflammation and complement activation in Alzheimer's disease[J]. Front Mol Biosci, 2021, 8:630869. doi:10.3389/fmolb.2021.630869.
[27]	HAO X, LI Z, LI W, et al. Periodontal infection aggravates c1q-mediated microglial activation and synapse pruning in Alzheimer's mice[J]. Front Immunol, 2022, 13:816640. doi:10.3389/fimmu.2022.816640.
[28]	WANG C, YUE H, HU Z, et al. Microglia mediate forgetting via complement-dependent synaptic elimination[J]. Science, 2020, 367(6478):688-694. doi:10.1126/science.aaz2288.
[29]	QIN Q, WANG M, YIN Y, et al. The Specific mechanism of TREM2 regulation of synaptic clearance in Alzheimer's disease[J]. Front Immunol, 2022, 13:845897. doi:10.3389/fimmu.2022.845897.
[30]	SPURRIER J, NICHOLSON L, FANG X T, et al. Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q[J]. Sci Transl Med, 2022, 14(647):eabi8593. doi:10.1126/scitranslmed.abi8593.
[31]	CARPANINI S M, TORVELL M, BEVAN R J, et al. Terminal complement pathway activation drives synaptic loss in Alzheimer's disease models[J]. Acta Neuropathol Commun, 2022, 10(1):99. doi:10.1186/s40478-022-01404-w.
[32]	LEE H E, LIM D, LEE J Y, et al. Recent tau-targeted clinical strategies for the treatment of Alzheimer's disease[J]. Future Med Chem, 2019, 11(15):1845-1848. doi:10.4155/fmc-2019-0151.
[33]	HU J, YANG Y, WANG M, et al. Complement C3a receptor antagonist attenuates tau hyperphosphorylation via glycogen synthase kinase 3β signaling pathways[J]. Eur J Pharmacol, 2019, 850:135-140. doi:10.1016/j.ejphar.2019.02.020.
[34]	YAO Y, CHANG Y, LI S, et al. Complement C3a receptor antagonist alleviates tau pathology and ameliorates cognitive deficits in P301S mice[J]. Brain Res Bull, 2023, 200:110685. doi:10.1016/j.brainresbull.2023.110685.
[35]	JUN G R, YOU Y, ZHU C, et al. Protein phosphatase 2A and complement component 4 are linked to the protective effect of APOE ɛ2 for Alzheimer's disease[J]. Alzheimers Dement, 2022, 18(11):2042-2054. doi:10.1002/alz.12607.
[36]	JEVTIC S, SENGAR A S, SALTER M W, et al. The role of the immune system in Alzheimer disease:Etiology and treatment[J]. Ageing Res Rev, 2017, 40:84-94. doi:10.1016/j.arr.2017.08.005.
[37]	HANSEN D V, HANSON J E, SHENG M. Microglia in Alzheimer's disease[J]. J Cell Biol, 2018, 217(2):459-472. doi:10.1083/jcb.201709069.
[38]	LANDLINGER C, OBERLEITNER L, GRUBER P, et al. Active immunization against complement factor C5a:A new therapeutic approach for Alzheimer's disease[J]. J Neuroinflammation, 2015, 12:150. doi:10.1186/s12974-015-0369-6.
[39]	DEJANOVIC B, HUNTLEY M A, DE MAZIÈRE A, et al. Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies[J]. Neuron, 2018, 100(6):1322-1336.e7. doi:10.1016/j.neuron.2018.10.014.
[40]	HETTMANN T, GILLIES S D, KLEINSCHMIDT M, et al. Development of the clinical candidate PBD-C06,a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation[J]. Sci Rep, 2020, 10(1):3294. doi:10.1038/s41598-020-60319-5.
[41]	CHEN H, DENG C, MENG Z, et al. Effects of catalpol on Alzheimer's disease and its mechanisms[J]. Evid Based Complement Alternat Med, 2022,2022:2794243. doi:10.1155/2022/2794243.

补体系统激活参与阿尔茨海默病的研究进展

Research progress on the activation of complement system is involved in the pathogenesis of Alzheimer's disease

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 41

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈晶晶, 农章嵩, 谭良源, 杨培培, 梁英业, 唐宏亮, 王开龙. 小胶质细胞极化在神经病理性疼痛中作用研究进展[J]. 天津医药, 2024, 52(9): 1000-1003.
[2]	刘斌, 杨龙, 李文莉, 邵宁宁, 董津睿. 小胶质细胞铁死亡在烟雾吸入性脑损伤中的作用机制探讨[J]. 天津医药, 2024, 52(8): 791-797.
[3]	贾西瑞, 刘莉洁. 小胶质细胞在脓毒症相关性脑病中的作用及研究进展[J]. 天津医药, 2024, 52(5): 557-560.
[4]	肖雨倩, 孙可心, 万俊, 陈淑颖, 陈丽敏, 王岩, 白艳杰. RNA m6A甲基化在卒中后认知障碍中的研究进展[J]. 天津医药, 2024, 52(3): 331-336.
[5]	欧阳杰, 赵海倩, 孔云, 牛钦, 陈莹, 思永玉. 电针对紫杉醇诱导大鼠神经病理性疼痛的影响[J]. 天津医药, 2024, 52(11): 1141-1145.
[6]	冉龙飞, 聂志强, 郭军辉. 数字化技术在阿尔茨海默病中的应用进展[J]. 天津医药, 2024, 52(10): 1106-1109.
[7]	王翠, 杨畅, 金玉, 高蜜, 张雯, 王琼, 金海涛. 木犀草苷对阿尔茨海默病模型细胞凋亡和炎性因子表达的研究[J]. 天津医药, 2023, 51(7): 701-706.
[8]	丁雨潇, 粟璟曦, 宋琼, 王丽惠, 吴日宝, 况昕宇, 苏迎, 邹春林. 食蟹猴纹状体内注射α-突触核蛋白预制原纤维对嗅球病理改变的影响[J]. 天津医药, 2023, 51(6): 586-589.
[9]	李晓晓, 白艳杰, 王岩, 张雍闯, 陈丽敏, 陈淑颖. 高脂饮食与认知障碍关系的研究进展[J]. 天津医药, 2023, 51(4): 441-444.
[10]	张赟, 李珂, 补王珍. 电针调控Nrf2/HO-1通路对缺血缺氧性脑损伤大鼠小胶质细胞活化的影响[J]. 天津医药, 2023, 51(2): 149-154.
[11]	陈俊, 郑锦豪, 陈家良, 陈博. 阿尔茨海默病患者血清GGT、CTHRC1表达水平检测及临床意义[J]. 天津医药, 2023, 51(2): 216-220.
[12]	赵佳佳, 万文军, 杨荷雨, 谢敏, 刘玲. ANA-12靶向抑制BDNF/TrkB信号缓解奥沙利铂诱导化疗大鼠的痛觉行为[J]. 天津医药, 2023, 51(1): 35-40.
[13]	抗晶晶, 曹翔. 石蒜碱通过TLR4/NF-κB途径抑制LPS诱导的原代小胶质细胞炎症反应[J]. 天津医药, 2022, 50(9): 897-901.
[14]	王琳, 李作孝. 黄芩素对实验性自身免疫性脑脊髓炎小鼠的影响及机制研究[J]. 天津医药, 2022, 50(4): 381-387.
[15]	唐颖林, 徐琼芳, 许立婷 . 法舒地尔对早产鼠脑白质损伤后OLs成熟及髓鞘形成的影响[J]. 天津医药, 2022, 50(2): 160-166.